ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02203825
Recruitment Status : Completed
First Posted : July 30, 2014
Last Update Posted : June 1, 2018
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Celyad (formerly named Cardio3 BioSciences)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2018
  Actual Study Completion Date : March 2018